A Breakthrough in Exosome Skincare ft. Madhavi Gavini of Droplette

Send us Fan Mail

In this special episode of Skin Anarchy, Dr. Ekta Yadav welcomes back Madhavi Gavini, founder of Droplette—one of the earliest science-forward brands featured on the show. What once felt like a radically different approach to skincare technology now feels increasingly relevant as the industry shifts toward biologics, regenerative ingredients, and delivery science. The conversation revisits Droplette’s origins and explores why effective delivery may be the missing piece in modern skincare innovation.

Gavini’s journey into skincare began far outside the beauty industry. With a background in pharmaceutical development, she spent years designing therapies for pediatric diseases, where she encountered one of medicine’s most persistent challenges: delivery. Even when researchers identify the therapeutic molecule that could help treat a condition, getting that molecule into the correct layer of skin is often the hardest part. That realization became the foundation of Droplette’s technology, originally developed alongside MIT-affiliated researchers to enable large molecules to reach skin tissue without needles or barrier injury.

The Droplette device generates high-velocity, submicron droplets capable of moving ingredients past the stratum corneum—the skin’s protective outer barrier—allowing molecules far larger than traditional topical ingredients to access viable layers of skin. The implications extend beyond cosmetics, with ongoing collaborations exploring delivery for antibiotics, gene therapies, and other advanced biologics.

The episode also dives into the science behind exosomes—one of the most talked-about yet misunderstood areas in regenerative skincare. Gavini explains what exosomes are, why sourcing and stability matter, and why many topical exosome products degrade or fail to penetrate the skin barrier. Double Board-Certified Dermatologist, Dr. Dan Belkin, also shares his clinical perspective on how exosomes are currently used in dermatology and why reliable sourcing, cold-chain handling, and effective delivery systems are essential for maintaining biological activity.

Listen to the full episode to hear Madhavi Gavini explain how Droplette is bringing pharmaceutical-grade delivery science into the future of regenerative skincare.

Use discount code 'ANARCHY' to get the Exosome Starter Set on subscription for just $349

SHOP DROPLETTE

1.Quek BL, Srinivas RL, Gavini MP. Droplette: a platform technology to directly deliver nucleic acid therapeutics and other molecules into cells and deep into tissue without transfection reagents. Methods Mol Biol. 2022;2398:211-230. doi:10.1007/978-1-0716-1811-0_14.

2.Mahmood A, et al. Droplette—a fluid dynamics-driven platform for transdermal and intracellular delivery of large molecules. FASEB J. 2018;31(S1):924.7.

3.Pulakat L, Chen HH, Gavini MP, Ling LA, Tang Y, Mehm A, et al. Transdermal delivery of high molecular weight antibiotics to deep tissue infections via Droplette Micromist Technology Device (DMTD). Pharmaceutics. 2022;14(6):1134

*This is a sponsored collaboration

Support the show